Vorinostat is an anti-cancer drug used to treat cutaneous T-cell lymphoma. However, during its production, impurities may be formed that can affect the quality and efficacy of the drug. These impurities can be organic or inorganic and can arise from various sources such as starting materials, reagents, and intermediates. It is critical to identify and control these impurities to ensure the safety and effectiveness of the drug.
